Literature DB >> 9634820

The extreme sensitivity of Mycobacterium tuberculosis to the front-line antituberculosis drug isoniazid.

V Deretic1, E Pagán-Ramos, Y Zhang, S Dhandayuthapani, L E Via.   

Abstract

Mycobacterium tuberculosis is a natural mutant in oxyR, a close homolog of the central regulator of peroxide stress response in enteric bacteria. Inactivation of oxyR is specific for M. tuberculosis and other members of the M. tuberculosis complex. This phenomenon appears as a paradox due to the ability of this organism to parasitize host macrophages, in which the ingested organisms are likely to be exposed to reactive oxygen intermediates. However, the surprising finding that M. tuberculosis has multiple deletions, nonsense and frameshift mutations in oxyR may help explain the exceptionally high sensitivity of M. tuberculosis to the potent antituberculosis agent isoniazid. One of the genes affected by oxyR lesions, ahpC (encoding an alkylhydroperoxide reductase) may determine the intrinsic sensitivity of mycobacteria to isoniazid.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 9634820     DOI: 10.1038/nbt1196-1557

Source DB:  PubMed          Journal:  Nat Biotechnol        ISSN: 1087-0156            Impact factor:   54.908


  15 in total

1.  Contribution of kasA analysis to detection of isoniazid-resistant Mycobacterium tuberculosis in Singapore.

Authors:  A S Lee; I H Lim; L L Tang; A Telenti; S Y Wong
Journal:  Antimicrob Agents Chemother       Date:  1999-08       Impact factor: 5.191

2.  Alkyl hydroperoxide reductases C and D are major antigens constitutively expressed by Mycobacterium avium subsp. paratuberculosis.

Authors:  I Olsen; L J Reitan; G Holstad; H G Wiker
Journal:  Infect Immun       Date:  2000-02       Impact factor: 3.441

3.  A ferritin mutant of Mycobacterium tuberculosis is highly susceptible to killing by antibiotics and is unable to establish a chronic infection in mice.

Authors:  Ruchi Pandey; G Marcela Rodriguez
Journal:  Infect Immun       Date:  2012-07-16       Impact factor: 3.441

4.  Silencing of oxidative stress response in Mycobacterium tuberculosis: expression patterns of ahpC in virulent and avirulent strains and effect of ahpC inactivation.

Authors:  B Springer; S Master; P Sander; T Zahrt; M McFalone; J Song; K G Papavinasasundaram; M J Colston; E Boettger; V Deretic
Journal:  Infect Immun       Date:  2001-10       Impact factor: 3.441

5.  Mapping of Mycobacterium tuberculosis katG promoters and their differential expression in infected macrophages.

Authors:  S Master; T C Zahrt; J Song; V Deretic
Journal:  J Bacteriol       Date:  2001-07       Impact factor: 3.490

6.  Oxidative stress response and characterization of the oxyR-ahpC and furA-katG loci in Mycobacterium marinum.

Authors:  E Pagán-Ramos; J Song; M McFalone; M H Mudd; V Deretic
Journal:  J Bacteriol       Date:  1998-09       Impact factor: 3.490

7.  OsmC proteins of Mycobacterium tuberculosis and Mycobacterium smegmatis protect against organic hydroperoxide stress.

Authors:  Sankaralingam Saikolappan; Kishore Das; Smitha J Sasindran; Chinnaswamy Jagannath; Subramanian Dhandayuthapani
Journal:  Tuberculosis (Edinb)       Date:  2011-11-15       Impact factor: 3.131

8.  Requirements for nitric oxide generation from isoniazid activation in vitro and inhibition of mycobacterial respiration in vivo.

Authors:  Graham S Timmins; Sharon Master; Frank Rusnak; Vojo Deretic
Journal:  J Bacteriol       Date:  2004-08       Impact factor: 3.490

9.  Nitric oxide generated from isoniazid activation by KatG: source of nitric oxide and activity against Mycobacterium tuberculosis.

Authors:  Graham S Timmins; Sharon Master; Frank Rusnak; Vojo Deretic
Journal:  Antimicrob Agents Chemother       Date:  2004-08       Impact factor: 5.191

10.  Molecular and physiological effects of mycobacterial oxyR inactivation.

Authors:  Eileen Pagán-Ramos; Sharon S Master; Christopher L Pritchett; Renate Reimschuessel; Michele Trucksis; Graham S Timmins; Vojo Deretic
Journal:  J Bacteriol       Date:  2006-04       Impact factor: 3.490

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.